Vaccinated individuals in the cohort received a vaccine against SARS-CoV-2 in Denmark (approved by the European Medicines Agency) and were followed up from the date of vaccination with the first dose (with BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 (AstraZeneca), or Ad26.COV2.S (Johnson and Johnson)). Only estimates for individuals vaccinated with BNT162b2 or mRNA-1273 are presented in the main analysis. Estimates for individuals vaccinated with ChAdOx1 nCoV-19 or Ad26.COV2.S are presented in the supplemental materials, because these vaccines were withdrawn from the national mass vaccination programme and rarely used. The main risk window of interest was the 28 days after vaccination, which included day 0, the day of vaccination. If study participants received a second dose, they re-entered a 28 day risk window.
Mrna 1273
Manufactured by AstraZeneca
MRNA-1273 is a laboratory product designed for research purposes. It is a messenger RNA (mRNA) molecule that serves as a template for the production of a specific protein. The core function of MRNA-1273 is to provide a means for studying and understanding mRNA-based technologies and their potential applications.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using mrna 1273
1
SARS-CoV-2 Vaccine Efficacy Assessment
2
COVID-19 Vaccination Program in Scotland
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The COVID-19 vaccination programme in Scotland began on 8 December 2021. Initial priority groups included care home residents and staff, front line health and social care workers and clinically extremely vulnerable individuals. Initially the Pfizer BNT162b2 product (hereafter Pfizer vaccine) was used. From 8 January 2021 the AstraZeneca ChAdOx1 product (hereafter AstraZeneca vaccine) was introduced and from 7 April 2021 the Moderna mRNA-1273 product (hereafter Moderna vaccine) was introduced. CHI number, date of administration, age at vaccination, vaccine product name, whether first or second dose were extracted for all 6894008 vaccination records from 4 December 2020 to 15 July 2021 from the national vaccination database.
3
Defining COVID-19 Vaccination Status
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We defined complete primary vaccination according to the criteria set by the WHO: (a) two doses of the BNT162 (Pfizer), mRNA-1273 (Moderna), or ChAdOx1-S (Oxford/AstraZeneca) vaccines; or (b) a single dose of Janssen Ad26.COV2.S [22 ]. Incomplete vaccination was defined as receiving only a single dose of the BNT162 (Pfizer), mRNA-1273 (Moderna), or ChAdOx1-S (Oxford/AstraZeneca) vaccines. Booster vaccinations were defined as any additional doses administered after completing the primary vaccination series [22 ].
4
Headache Incidence After COVID-19 Vaccines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The primary endpoint was to assess the number of admissions and the etiology of new or worsening headaches within 16 days after the administration of COVID-19 vaccines. In particular, the number of admissions and hospitalizations in the pre-COVID-19 era (January 2019–January 2020) vs. the COVID-19 vaccination period (January 2021–January 2022) were collected and compared.
Furthermore, the number of hospitalizations for new or worsening headaches following the COVID-19 vaccine was compared with the number of hospitalizations for headaches not associated with the COVID-19 vaccine.
Secondary endpoints were: the identification of headache characteristics (type of pain, localization, pain intensity, associated neurological and/or systemic symptoms, initial clinical suspicion, diagnosis at discharge); the clinical course during hospitalization; and the identification of possible clinical and biohumoral markers, which could predict symptomatic headaches and the type of COVID-19 vaccine involved (Pfizer-BioNTech—Comirnaty, Moderna—mRNA-1273, AstraZeneca—Vaxzevria, and Johnson & Johnson—Janssen).
Furthermore, the number of hospitalizations for new or worsening headaches following the COVID-19 vaccine was compared with the number of hospitalizations for headaches not associated with the COVID-19 vaccine.
Secondary endpoints were: the identification of headache characteristics (type of pain, localization, pain intensity, associated neurological and/or systemic symptoms, initial clinical suspicion, diagnosis at discharge); the clinical course during hospitalization; and the identification of possible clinical and biohumoral markers, which could predict symptomatic headaches and the type of COVID-19 vaccine involved (Pfizer-BioNTech—Comirnaty, Moderna—mRNA-1273, AstraZeneca—Vaxzevria, and Johnson & Johnson—Janssen).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!